AVANIR PHARMACEUTICALS Summary Consolidated Financial Information (Unaudited)

Statement of Operations Data:

Quarters Ended December 31      2001    2000    Revenues $ 6,130,215  $ 5,065,732    Expenses           Research and development 2,346,859  1,308,125        General and administrative 954,068  772,695        Sales and marketing 320,032  214,319        Total operating expenses 3,620,959  2,295,139    Income from operations $ 2,509,256  $ 2,770,593        Interest income 187,915  335,370        Other income 82,940  -         Interest expense (14,602)  (2,859)    Net income $ 2,765,509  $ 3,103,104    Net income attributable to      common shareholders $ 2,754,650  $ 3,092,144    Net income per share:               Basic $ 0.05  $ 0.05            Diluted $ 0.04  $ 0.05    Weighted average number of     common shares outstanding:               Basic 58,029,403  57,216,732            Diluted 61,455,499  65,516,875

Consolidated Balance Sheet Data:

December 31, 2001    September 30, 2001    Cash and cash equivalents $ 12,546,173  $ 16,542,545    Short and long-term investments $ 11,709,478  $ 5,308,691    Net working capital $ 12,587,458  $ 16,415,699    Total assets $ 29,930,874  $ 27,053,953    Total liabilities $ 2,670,050  $ 2,592,490    Redeemable convertible preferred stock $ 507,512  $ 502,903    Shareholders' equity $ 26,753,312  $ 23,958,560